1 / 64

Oncologic Emergencies

Oncologic Emergencies. Javier Oesterheld MD Pediatric Hematology/Oncology. Oncologic Emergencies. Superior Vena Cava Syndrome (SVCS) Superior Mediastinal Syndrome (SMS) Spinal Cord Compression Metabolic Emergencies Infectious Complications Assorted Complications.

cindy
Download Presentation

Oncologic Emergencies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Oncologic Emergencies Javier Oesterheld MD Pediatric Hematology/Oncology

  2. Oncologic Emergencies • Superior Vena Cava Syndrome (SVCS) • Superior Mediastinal Syndrome (SMS) • Spinal Cord Compression • Metabolic Emergencies • Infectious Complications • Assorted Complications

  3. Mediastinal Mass (SVCS/SMS)

  4. Mediastinal Mass

  5. Pathophysiology • SVCS • The SVC is thin walled and surrounded by lymph nodes and thymus • Tumor or infection in the lymph nodes or thymus can compress the SVC • SMS • The trachea and main stem bronchi are compressible in children and tumor or infection in surrounding lymph nodes can lead to compression

  6. SVCS and SMS • Etiologies • CV surgery • Shunting for hydrocephalus • Tumor • Most common primary cause • NHL, Hodgkin’s disease, ALL, GCT • Usually SCVS and SMS occur in the same patient

  7. Symptoms • Cough, hoarseness, dyspnea, orthopnea, and chest pain • More advanced: anxiety, confusion, lethargy, headache, distorted vision, syncope • Symptoms are aggravated when patient is supine or flexed

  8. Signs • Swelling, plethora and cyanosis of the face, neck and upper extremities • Suffusion and edema of the conjunctiva • Diaphoresis, wheezing, and stridor • Engorgement of the chest wall vessels • In children onset of symptoms are rapid

  9. Evaluation • Management/diagnostic decisions difficult and controversial - - emergency treatment vs definitive Dx • Significant stridor, dyspnea usually not present unless airway cross-sectional area narrowed by >50% • Some authors recommend CT scan to evaluate tracheal compression prior to decisions regarding sedation/anesthesia

  10. Evaluation • CXR • CT of Chest • AFP and beta HCG • Obtain diagnosis • The child may not tolerate GA – therefore the least invasive method of diagnosis should be used (i.e. CBC, BMA, Pleurocentesis)

  11. Evaluation • Inability to tolerate supine position of grave significance with anterior mediastinal mass • May result from weight of tumor compressing not only airway, but great vessels and heart (especially RV outflow tract) • If can tolerate supine position, CT and PFT’s may help indicate which children will tolerate anesthesia • Shamberger, 1991 and 1995

  12. Emergent Management • Keep child in sitting, left lateral decubitus position - - helps “lift” mass off airway and RVOT • IV access (lower extremities preferable due to SVC obstruction) • Face mask O2, non-invasive PEEP • Last resort is intubation!

  13. Emergent Management • AVOID sedation for procedures unless anesthesiologist present and prepared for VERY difficult intubation • If impending respiratory failure and requires intubation . . . • Awake, bronchoscopic intubation ideal to maintain airway muscle tone, prevent worsened extrinsic compression • Ideally, have cardiopulmonary bypass available • AVOID neuromuscular blockade - - worsened obstruction even as low as carina

  14. Therapy • Clot in SVC – Thrombolytic agent (TPA) • SMS – true emergency • Obtain Dx if possible • XRT • Often rapid improvement • There can be post irradiation tracheal swelling and deterioration • Chemotherapy • Steroids, cytoxan

  15. Spinal Cord Compression • Occurs in 3-5% of children with cancer, often at diagnosis. • Can occur with any tumor type, but mostly with Leukemia, NHL neuroblastoma, sarcoma, and Hodgkin’s disease.

  16. Spinal Cord Compression • Pathogenesis • Epidural compression most common in children • Metastatic tumor to vertebral body and secondary compression (Common in adults) is not common in children

  17. Presentation Back Pain: suspect cord compression when . . . pain not relieved in supine position or back pain has a radicular component. • Weakness, sensory abnormalities, and paresis. • Paraplegia and quadriplegia can occur rapidly if there are neurologic abnormalities • Urinary and fecal incontinence.

  18. Spinal Cord Compression • Signs and symptoms • Back pain in 80% • Abnormal neuro exam (esp. decreased motor strength)

  19. Spinal Cord Compression • Evaluation • Plain films – 50% are normal • MRI • Therapy • Dexamethasone (initiate quickly if compression is a consideration) • Surgical decompression (unknown Primary) • Radiation therapy • Chemotherapy

  20. Treatment • Symptoms of cord dysfunction: give dexamethasone and obtain MRI • Decompression: surgery, radiation, chemotherapy. • Surgery indicated if tumor type is not known or symptoms progress despite radiotherapy. • Chemotherapy is appropriate for patients with spinal cord compression due to lymphoma, leukemia, and neuroblastoma.

  21. Metabolic Emergencies – Tumor Lysis Syndrome • TLS – is a consequence of rapid release of intracellular metabolites (uric acid, K+, phosphate) in quantities that exceed the excretory capacity of the kidneys • Usually occurs at diagnosis or within 5 days of starting therapy

  22. Tumor Lysis Syndrome • Metabolic manifestations include • Increase UA, K+, phos • Secondary decreased calcium and cardiac arrhythmias • Renal failure • Most commonly seen in hematologic malignancies • Lymphoma (esp. Burkitt’s) • ALL • AML

  23. Tumor Lysis Syndrome • Pathophysiology • Massive lyses of malignant cells • Worsened by inadequate renal function • Accelerated by treatment • Uric acid (calcium phosphate) precipitates in the kidney, causing worsening kidney function

  24. Consequences of tumor lysis syndrome • Hyperkalemia  weakness, dysrhythmias • Hyperphosphatemia  hypocalcemia, renal failure • Hypocalcemia  tetany, mental status changes, seizures • Hyperuricemia  “uric acid nephropathy” = oliguria, renal failure

  25. Tumor Lysis Syndrome • Labs to be obtained in at risk patients • CBC with diff • Electrolytes, BUN, creat, Ca++, Phos-, uric acid, LDH, and UA • CXR • If K+ increased, EKG looking for peaked T waves and/or QRS widening

  26. Tumor Lysis Syndrome • Management • High Risk Patients • Burkitt’s lymphoma • Other NHL • Leukemia with increased WBC • Decreased urine output, increased creat • Metabolic abnormalities

  27. Tumor Lysis Syndrome • Management (cont.) • Before cytotoxic chemotherapy started, metabolic stability should be achieved • For decreased urine output do renal US to R/O obstructive uropathy • Hydration • 3000cc/msq/d – NO K+ • Maintain SG < 1.010 and /or 4cc/kg/hr

  28. Tumor Lysis Syndrome • Management (cont.) • Alkalinization • > 50meq/L NaHCO3 – adjust to keep ph 7.0 – 7.5 • Diamox 150 – 1000mg/msq/d divided q6 • Avoid ph > 7.5 due to crystallization of CaPhos • Allopurinol – 300 mg/msq/day po or IV • Rasburicase

  29. Tumor Lysis Syndrome • Hypoxanthine* Xanthine* Uric Acid-> Allantoin • *Xanthine Oxidase involved in reaction • Inhibited by Allopurinol • Urate Oxidase involved in reaction Uric Acid -> Allantoin • Allantoin more soluble than UA or Xanthine • Recombinant urate oxidase (Rasburicase) used for severe TLS

  30. Tumor Lysis Syndrome • Management • Inadequate urine output • Lasix 0.5 – 1 mg/kg q4 hr or 1mg/kg/hr CI • Mannitol 15 gm/msq q6 hr IV over 30 min • Hyperkalemia - > 6.0 – 6.5 meq/L with EKG changes • Kayexalate: 1 gm/kg po or pr with 50% sorbitol • Insulin (Reg 0.1 u/kg) in 2 cc/kg 25% DEX IV • Initiate steps to begin dialysis

  31. Tumor Lysis Syndrome • Management • Hyperphosphatemia • Aluminum hydroxide (Amphogel) : 50 – 150 mg/kg/d with meals • Hypocalcemia, symptomatic • 10% calcium gluconate 0.5 – 1 mg/kg IV • Dialysis

  32. 5-20% of children with new Dx of leukemia have WBC count > 100,000/mm3 These patients at risk of severe complications from hyperviscosity of blood Hyperleucocytosis

  33. Hyperleukocytosis - Complications • Blasts interact with endothelium to form aggregates, thrombi in microcirculation • Most problems in CNS and pulmonary circulation • Complications more common with AML than ALL • Myeloblasts and monoblasts larger, less deformible, “stickier”

  34. Pulmonary leukostasis • Sx: dyspnea, tachypnea, hypoxemia, acidosis, cor pulmonale • CXR: diffuse interstitial infiltrates

  35. CNS Manifestations • Headache, mental status changes, seizures, coma in spectrum of Sx • High risk of intracranial hemorrhage, especially with AML and thrombocytopenia

  36. Therapy for hyperleukocytosis • Decrease blood viscosity (directly related to morbidity) • Hydration • AVOID use of diuretics • AVOID PRBC transfusion (Hb goal < 10 gm/dL for viscosity) • Transfuse platelets to keep > 20,000/mm3 and treat coagulopathy (common with AML) to decrease risk of intracranial hemorrhage

  37. Therapy for hyperleukocytosis • Urine alkalinization, hydration, etc as with tumor lysis syndrome • Consider leukapheresis or exchange transfusion • PICU supportive care - mechanical ventilation, hemodynamic support, etc

  38. Same diagnostic criteria as other pts: Fever/hypothermia Tachycardia Tachypnea Hypoperfusion Acidosis Hypotension (SCCM/ACCP Consensus Conference, 1992) Common etiologies: Gram + cocci -hemolytic Strep Staph. Epi Staph aureus Gram - rods Pseudomonas Enterobacter E. coli Fungi Candida spp Viruses Sepsis in Pediatric Cancer Patients

  39. Infectious Complications • Risk Factors • Alterations of cellular and humoral immunity • Disruption of natural barriers • Colonization with more pathogenic organisms • Abnormalities of lymphocytic, spleen, and RES • Decreased PMN

  40. Infectious Complications • Definition • Fever • >38.5 or 38.0 twice within 12 hour period • Neutropenia • ANC < 500 or less than 1000 and predicted to be less than 500 within 24 – 48 hours

  41. Infectious Complications • Fever – Nonneutropenic/No CV line • PE – non toxic child • No source of infection or defined non-life threatening source • Obtain blood and urine cultures and other appropriate cultures • Treat identified infection as appropriate • Close F/U, no hospitalization or IV antibiotics necessary

  42. Infectious Complications • Fever – Non-neutropenic/indwelling CV line • PE - non-toxic child, no evidence of likely systemic infection • Blood cultures through all lumens • Urine culture and other cultures as appropriate • Hospitalization and IV antibiotics • Coverage for both gram + and gram – organisms • Continue antibiotics for 48 – 72 hours and then D/C if cultures negative • Observation with or w/o IV antibiotics also acceptable

  43. Infectious Complications • Fever/Neutropenic patient • Thorough history and PE • Especially sites commonly a source of infection: skin, lungs, perioral, and perirectal area • Subtle signs of inflammation should be considered signs of infection • Blood and urine cultures and other cultures as appropriate • CXR, LP, wound cultures as appropriate • Hospitalize and treat with IV antibiotics

  44. Infectious Complications • Consideration for antibiotic choice • < 50% will have defined site of infection • 85 – 90% of identified pathogens associated with new fever in neutropenic patients are bacterial • Gram (+) and Gram (–) bacteria involved

  45. Infectious Complications • Treatment considerations • Documented infections are treated 10 – 14 days • Patients can be divided into 2 risk groups • Low risk group – ANC expected to recover within 7 days and there is no co-morbidity (decreased BP, respiratory compromise, altered MS) • High risk group – ANC expected to be low for > 7 days

  46. Infectious Complications • Treatment Duration • Low risk group – D/C antibiotics when ANC recovering (increasing monos/platelets/WBC) and blood cultures negative and afebrile for 24 hours • High risk group • Patients who become afebrile within 7 days but remain neutropenic should have antibiotics continued until ANC recovering or 14 days

  47. Infectious Complications • High risk group who remains febrile >3-4 days • Continue antibiotics, but add antifungal therapy • If Abx were stopped in febrile neutropenic patients at day 7, 56% developed symptoms of infection with 3 days, 36 % presented with hypotension • If Abx continued 31 % developed invasive fungal

  48. Infectious Complications • Rationale of treatment for high risk group • In patients who became afebrile but remained neutropenic and had antibiotics stopped at day 7, 41% became febrile within 3 days – 0% became febrile if antibiotics continued • Patients who were afebrile but neutropenic and had antibiotics stopped at day 14 had the same incidence of recurrent fevers as those who continued on antibiotics past 14 days – 30%

More Related